Adept Therapeutics
Biotechnology, 48 Dunham Rd, BEVERLY, Massachusetts, 01915, United States, 1-10 Employees
Phone Number: +19*********
Who is ADEPT THERAPEUTICS
Adept Therapeutics Inc. (AdeptTx) is an innovative start-up biotech company located at Beverly in Great Boston area, MA, with passion and commitment to discover and develop potentially li...
Read More
-
Headquarters: 48 Dunham Rd, BEVERLY, Massachusetts, 01915, United States
-
Employees: 1-10
-
Revenue: Under $1 Million
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from ADEPT THERAPEUTICS
Adept Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Adept Therapeutics
Answer: Adept Therapeutics's headquarters are located at 48 Dunham Rd, BEVERLY, Massachusetts, 01915, United States
Answer: Adept Therapeutics's phone number is +19*********
Answer: Adept Therapeutics's official website is https://adepttx.com
Answer: Adept Therapeutics's revenue is Under $1 Million
Answer: Adept Therapeutics's SIC: 8731
Answer: Adept Therapeutics has 1-10 employees
Answer: Adept Therapeutics is in Biotechnology
Answer: Adept Therapeutics contact info: Phone number: +19********* Website: https://adepttx.com
Answer: Adept Therapeutics Inc. (AdeptTx) is an innovative start-up biotech company located at Beverly in Great Boston area, MA, with passion and commitment to discover and develop potentially life-changing medicines for people with unmet medical needs. Focusing on T cells, Natural Killer cells and immune-suppressive myeloid cells, we leverage multiple advanced antibody technologies to discover fully human or humanized antibody therapeutics to enhance anti-tumor immunity. We are establishing and optimizing two unique platforms including immune cell engager bispecific antibodies and multi-functional tri-specific antibodies, which change tumor microenvironment (TME) to boost immune responses against cancer cells through 1) recruiting and activating effector immune cells and 2) modulating immune-suppressive TME to support tumor killing effector cell function. Our expertise in GPCR antibody discovery and development enable us to reach for the high-hanging fruits, the most challenging targets for antibody therapeutics discovery . Our broad product portfolio focuses on both hematological malignancies, such as cutaneous lymphoma, and solid tumors including triple negative breast cancer, ovarian, colon, kidney, renal, prostate, and pancreatic cancers etc.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month